spironolactone has been researched along with Asystole in 19 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study sought to investigate sex differences in outcomes and responses to spironolactone in patients with heart failure with preserved ejection fraction (HFpEF)." | 9.30 | Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. ( Kao, DP; Lindenfeld, J; Merrill, M; Sweitzer, NK, 2019) |
| " A randomized controlled trial of patients with heart failure and an ejection fraction > 45% showed that spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure." | 8.93 | Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes? ( Onarecker, C, 2016) |
| "The TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) trial randomized patients with HFpEF and either prior hospitalization for HF or elevated natriuretic peptide levels (B-type NP [BNP] ≥100 pg/ml or N-terminal proBNP ≥360 pg/ml) to spironolactone or placebo." | 7.85 | Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. ( Anand, IS; Claggett, B; Desai, AS; Fleg, JL; Liu, J; O'Meara, E; Pfeffer, MA; Pitt, B; Rector, TS; Shah, AM; Shah, SJ; Solomon, SD, 2017) |
| "In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia." | 7.71 | Serious adverse events experienced by patients with chronic heart failure taking spironolactone. ( Berry, C; McMurray, JJ, 2001) |
| "This study sought to investigate sex differences in outcomes and responses to spironolactone in patients with heart failure with preserved ejection fraction (HFpEF)." | 5.30 | Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. ( Kao, DP; Lindenfeld, J; Merrill, M; Sweitzer, NK, 2019) |
| "This study assessed the relationship between atrial fibrillation (AF) and outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial, to evaluate whether AF modified the treatment response to spironolactone and whether spironolactone influenced post-randomization AF." | 5.27 | Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. ( Anand, IS; Cikes, M; Claggett, B; Desai, AS; Fang, JC; Lewis, EF; O'Meara, E; Pfeffer, MA; Pitt, B; Rouleau, JL; Saksena, S; Shah, AM; Shah, SJ; Solomon, SD; Sweitzer, NK, 2018) |
| " A randomized controlled trial of patients with heart failure and an ejection fraction > 45% showed that spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure." | 4.93 | Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes? ( Onarecker, C, 2016) |
| " Compared with placebo, across all eGFR categories, spironolactone was associated with lower relative risk for the primary efficacy outcome and for hypokalemia, but higher relative risk for hyperkalemia, worsening renal function, and drug discontinuation." | 3.91 | Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. ( Beldhuis, IE; Claggett, B; Damman, K; Desai, AS; Fang, JC; Lewis, EF; Myhre, PL; O'Meara, E; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Voors, AA, 2019) |
| "The TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) trial randomized patients with HFpEF and either prior hospitalization for HF or elevated natriuretic peptide levels (B-type NP [BNP] ≥100 pg/ml or N-terminal proBNP ≥360 pg/ml) to spironolactone or placebo." | 3.85 | Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. ( Anand, IS; Claggett, B; Desai, AS; Fleg, JL; Liu, J; O'Meara, E; Pfeffer, MA; Pitt, B; Rector, TS; Shah, AM; Shah, SJ; Solomon, SD, 2017) |
| "The combination of spironolactone with an ACE inhibitor for patients with heart failure may cause severe hyperkalemia." | 3.73 | [Successful resuscitation of a patient with hyperkalemic cardiac arrest by emergency hemodiafiltration]. ( Gütlich, D; Hochscherf, M; Hopf, HB, 2005) |
| "A case of 80-year-old woman with marked hyperkalemia in the course of chronic treatment with angiotensin converting enzyme (ACE) inhibitors and spironolactone is presented." | 3.73 | [Ineffective atrial pacing and cardiac arrest in a 80-year old woman with hyperkalemia]. ( Bednarek, J; Czunko, A; Lelakowski, J; Majewski, J; Małecka, B; Pasowicz, M, 2005) |
| "In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia." | 3.71 | Serious adverse events experienced by patients with chronic heart failure taking spironolactone. ( Berry, C; McMurray, JJ, 2001) |
| "Additionally, ischemic heart disease adversely impacts the clinical course of HFrEF patients; however, its role in HFpEF is not fully understood." | 3.01 | Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). ( Elsaid, O; McCullough, PA; Rahimi, G; Tecson, KM, 2021) |
| "The association between low blood pressure (BP) levels and increased mortality has been established in several studies of heart failure (HF)." | 1.35 | Association of blood pressure and its evolving changes with the survival of patients with heart failure. ( Almendral, J; Bardaji, A; Bayes-Genis, A; Cinca, J; de Luna, AB; Fernandez-Palomeque, C; Gonzalez-JuAnatey, JR; Grigorian-Shamagian, L; Jimenez, RP; Macaya, C; Nieto, V; Pascual, D; Vazquez, R, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.79) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Kalra, R | 1 |
| Gupta, K | 1 |
| Sheets, R | 1 |
| Aryal, S | 1 |
| Ebrahimi, A | 1 |
| Rajapreyar, I | 1 |
| Cribbs, MG | 1 |
| Booker, OJ | 1 |
| Prabhu, SD | 1 |
| Bajaj, NS | 1 |
| Rahimi, G | 1 |
| Tecson, KM | 1 |
| Elsaid, O | 1 |
| McCullough, PA | 1 |
| Anand, IS | 4 |
| Claggett, B | 4 |
| Liu, J | 1 |
| Shah, AM | 3 |
| Rector, TS | 1 |
| Shah, SJ | 4 |
| Desai, AS | 4 |
| O'Meara, E | 4 |
| Fleg, JL | 2 |
| Pfeffer, MA | 5 |
| Pitt, B | 5 |
| Solomon, SD | 5 |
| Offman, R | 1 |
| Paden, A | 1 |
| Gwizdala, A | 1 |
| Reeves, JF | 1 |
| Onarecker, C | 1 |
| Cikes, M | 1 |
| Lewis, EF | 3 |
| Rouleau, JL | 1 |
| Sweitzer, NK | 3 |
| Fang, JC | 2 |
| Saksena, S | 1 |
| Basquin, C | 1 |
| Simeon, C | 1 |
| Gentili, ME | 1 |
| Beldhuis, IE | 1 |
| Myhre, PL | 1 |
| Damman, K | 1 |
| Voors, AA | 1 |
| Merrill, M | 1 |
| Lindenfeld, J | 1 |
| Kao, DP | 1 |
| Liu, L | 1 |
| Joseph, J | 1 |
| Claggett, BC | 1 |
| Huynh, T | 1 |
| Mckinlay, S | 1 |
| Grigorian-Shamagian, L | 1 |
| Gonzalez-JuAnatey, JR | 1 |
| Vazquez, R | 1 |
| Cinca, J | 1 |
| Bayes-Genis, A | 1 |
| Pascual, D | 1 |
| Fernandez-Palomeque, C | 1 |
| Bardaji, A | 1 |
| Almendral, J | 1 |
| Nieto, V | 1 |
| Macaya, C | 1 |
| Jimenez, RP | 1 |
| de Luna, AB | 1 |
| CHRISTIANSEN, J | 1 |
| HAGERUP, L | 1 |
| NIELSEN, B | 1 |
| Gütlich, D | 1 |
| Hochscherf, M | 1 |
| Hopf, HB | 1 |
| Lelakowski, J | 1 |
| Czunko, A | 1 |
| Majewski, J | 1 |
| Pasowicz, M | 1 |
| Małecka, B | 1 |
| Bednarek, J | 1 |
| Berry, C | 1 |
| McMurray, JJ | 1 |
| Ohmae, M | 1 |
| Nohara, Y | 1 |
| Takayasu, M | 1 |
| Saimyoji, H | 1 |
| Seriu, Y | 1 |
| Tormey, WP | 1 |
| Jina, AG | 1 |
| Stone, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure[NCT02627196] | 1,200 participants (Anticipated) | Interventional | 2016-04-19 | Active, not recruiting | |||
| Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)[NCT00094302] | Phase 3 | 3,445 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| A Phase 4, Randomized, Open Label, Multicenter Prospective Comparative Study To Evaluate The Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure[NCT04160000] | Phase 4 | 360 participants (Anticipated) | Interventional | 2020-07-26 | Recruiting | ||
| Randomized Clinical Trial of Radiofrequency Ablation for Atrial Fibrillation in Patients With Heart Failure With Preserved Ejection Fraction for Reduced Healthcare Utilization[NCT04327596] | 2 participants (Actual) | Interventional | 2021-01-25 | Terminated (stopped due to lack of enrollment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
First incidence of aborted cardiac arrest (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.09 |
| Spironolactone | 0.05 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 4.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 3.1 |
| Spironolactone | 2.8 |
Hospitalization for MI, stroke or the management of heart failure, whichever occurred first (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.2 |
| Spironolactone | 5.5 |
Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 102.33 |
| Spironolactone | 102.26 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 7.8 |
| Spironolactone | 7.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.6 |
| Spironolactone | 5.9 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
"Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 5.6 |
| Spironolactone | 5.1 |
First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.) (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 2.2 |
| Spironolactone | 3.2 |
First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.4 |
| Spironolactone | 1.4 |
Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mL/min/1.73m2 (Least Squares Mean) |
|---|---|
| Placebo | 67.50 |
| Spironolactone | 65.20 |
First incidence of a hospitalization for any reason (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 20.0 |
| Spironolactone | 18.8 |
First incidence of a hospitalization for the management of heart failure (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 3.8 |
First incidence of myocardial infarction (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.2 |
First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.7 |
| Spironolactone | 0.7 |
Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Spironolactone | 4.49 |
"Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.~The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition? Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.2 |
| Spironolactone | 1.2 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 65.9 |
| Spironolactone | 66.4 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 63.1 |
| Spironolactone | 64.4 |
Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 1.11 |
| Spironolactone | 1.17 |
Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 140.95 |
| Spironolactone | 140.33 |
First incidence of stroke (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 8.3 |
| Spironolactone | 6.8 |
1 review available for spironolactone and Asystole
| Article | Year |
|---|---|
Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes?
Topics: Cardiovascular Diseases; Heart Arrest; Heart Failure; Hospitalization; Humans; Mineralocorticoid Rec | 2016 |
4 trials available for spironolactone and Asystole
| Article | Year |
|---|---|
Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Creatinine; Diabetes Mellitus; Disease Progress | 2021 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
Topics: Age Factors; Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; | 2019 |
Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heart | 2015 |
14 other studies available for spironolactone and Asystole
| Article | Year |
|---|---|
Cardiac Function and Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Topics: Aged; Death, Sudden, Cardiac; Diastole; Echocardiography; Female; Heart Arrest; Heart Failure; Human | 2020 |
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Arrest; Heart Failure; Hospitalizati | 2017 |
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Arrest; Heart Failure; Hospitalizati | 2017 |
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Arrest; Heart Failure; Hospitalizati | 2017 |
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Arrest; Heart Failure; Hospitalizati | 2017 |
Hyperkalemia and cardiac arrest associated with glucose replacement in a patient on spironolactone.
Topics: Aged; Diabetes Mellitus; Emergency Treatment; Female; Glucose; Heart Arrest; Humans; Hyperkalemia; R | 2017 |
Peri-anaesthetic cardiac arrest with administration of enalapril, spironolactone and β-blocker.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Enalapril; Heart Arrest; Humans; Hyperka | 2018 |
Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Deprescriptions; Disease Progression; | 2019 |
QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiovascular Diseases; Cohort Studies; Electrocardi | 2016 |
Association of blood pressure and its evolving changes with the survival of patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium | 2008 |
HYPOKALEMIA AND HYPERTENSION; A PRESENTATION OF FOUR CASES INCLUDING A CASE OF PRIMARY ALDOSTERONISM.
Topics: Adrenal Gland Neoplasms; Drug Therapy; Geriatrics; Heart Arrest; Humans; Hydroflumethiazide; Hyperal | 1964 |
Ask the doctors. I've read that the medication spironolactone may cause cardiac arrest. Please discuss the pros and cons of this medicine. Does The Cleveland Clinic prescribe such a regimen for conditions after heart surgery?
Topics: Diuretics; Heart Arrest; Humans; Potassium; Spironolactone | 2005 |
[Successful resuscitation of a patient with hyperkalemic cardiac arrest by emergency hemodiafiltration].
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Cardiopulmonary Resuscitation; Diabet | 2005 |
[Ineffective atrial pacing and cardiac arrest in a 80-year old woman with hyperkalemia].
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Cardiac Pacing, Artificial; Electrocard | 2005 |
Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
Topics: Aged; Diarrhea; Diuretics; Fatal Outcome; Heart Arrest; Heart Failure; Humans; Hyperkalemia; Male; M | 2001 |
Paroxysmal atrial fibrillation with asystole and syncope: report of a case of sinus node dysfunction with hypokalemia and hypertension.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Heart Arrest; Humans; Hypertension; Hypokalemia; Male; Mi | 1976 |
Potassium-sparing diuretics and hyperkalaemia--still a problem.
Topics: Amiloride; Heart Arrest; Humans; Hyperkalemia; Potassium; Spironolactone | 1989 |